Table 1.
Descriptive analyses of study cohort
| Variable | Study Cohort, n = 377 |
|---|---|
| Age (mean ± SD), years | 49 ± 15 |
| Female gender, % | 44 |
| White, % | 71 |
| African American, % | 7 |
| American Indian, % | 7 |
| Hispanic | 13 |
| Family history of type 2 diabetes mellitus, % | 15 |
| Hemodialysis pretransplant, % | 63 |
| Peritoneal dialysis pretransplant, % | 12 |
| Recipient of preemptive TX, % | 25 |
| Hepatitis C seropositivity, % | 4 |
| Deceased donor, % | 35 |
| Pre-TX BMI > 30, % | 25 |
| Pre-TX triglyceride >200 mg/dl, % | 57 |
| Prednisone use at 1 month, % | 43 |
| Prednisone use at 4 months, % | 48 |
| Prednisone use at 12 months, % | 49 |
| Tacrolimus use at 4 months, % | 93 |
| Tacrolimus use at 12 months, % | 86 |
| Rapamune use at 12 months, % | 6 |